Showing results (81-90 of 117) with videos related to

Sort By:
Pageof 12
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|March 15, 2021
Awareness of myeloma care and the global impact of treatment: An international internet-based prospective studySikander Ailawadhi, Abhisek Swaika, Pooja Advani, et al.
Cancer|January 24, 2018
Trends in multiple myeloma presentation, management, cost of care, and outcomes in the Medicare population: A comprehensive look at racial disparitiesSikander Ailawadhi, Ryan D Frank, Mayank Sharma, et al.
Annals of Hematology|January 13, 2021
Utilization of radiation therapy in multiple myeloma: trends and changes in practiceSikander Ailawadhi, Ryan Frank, Meghna Ailawadhi, et al.
Blood Advances|May 19, 2020
Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8+ T-cell responsesAlak Manna, Timothy Kellett, Sonikpreet Aulakh, et al.
Anti-Cancer Drugs|August 16, 2019
Monoclonal antibody utilization characteristics in patients with multiple myelomaSikander Ailawadhi, Taimur Sher, Abdel-Ghani Azzouqa, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 5, 2019
Survival Trends in Young Patients With Multiple Myeloma: A Focus on Racial-Ethnic MinoritiesSikander Ailawadhi, Abdel-Ghani Azzouqa, David Hodge, et al.
Leukemia & Lymphoma|January 9, 2010
Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogeneticsTaimur Sher, Kena C Miller, David Lawrence, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2019
Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic LeukemiaAlak Manna, Sonikpreet Aulakh, Prachi Jani, et al.
Haematologica|April 21, 2019
Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman diseaseGaurav Goyal, Aishwarya Ravindran, Jason R Young, et al.
Blood Cancer Journal|October 2, 2019
Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemiaVivek Kumar, Sikander Ailawadhi, Leyla Bojanini, et al.
Pageof 12